Teacrineafv01.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Teacrineafv01.Pdf Estudos http://aformulabr.com.br/qrcode/teacrineafv01.pdf ® TEACRINE Os benefícios da cafeína com maior biodisponibilidade DESCRIÇÃO O TeaCrine® é um composto bioidêntico encontrado na natureza, com no mínimo 97% de teacrina, alcaloide presente na Camelia assamica e no café. MECANISMO DE AÇÃO O TeaCrine® age por 3 mecanismos de ação: inibe receptores adenosinérgicos (A1 e A2), responsáveis pela sensação de relaxamento e indução do sono, reduzindo a sensação de fadiga e cansaço, modula neurotransmissores e ativa receptores dopaminérgicos (D1 e D2) que elevam a atividade na região cerebral responsável pela recompensa e motivação, aumentando a energia e melhorando o humor, semelhante a cafeína, sem causar os efeitos indesejados (taquicardia e irritabilidade). INDICAÇÕES Fornece energia física e mental; aumento de performance; Promove motivação para o exercício; Aumenta o foco e concentração; melhora o humor; Reduz a fadiga. DOSE USUAL Recomendação oral de 50 a 200 mg de TeaCrine® ao dia. SUGESTÕES DE FÓRMULAS TeaCrine®......................................................... 100 mg TeaCrine®......................................................... 150 mg Beta-alanina...................................................... 300 mg Gengibre pó (Zingiber officinale) ........................... 100 mg Modo de uso: 1 dose ao dia, 30 minutos antes da Modo de uso: 1 dose ao dia, no período de maior atividade física. fadiga. Indicação: aumento da energia e motivação esportiva. Indicação: redução da fadiga. PRINCIPAIS REFERÊNCIAS BATISTUZZO, J. A O; ITAYA, M.; ETO, Y. Formulário Médico-Farmacêutico. 4 ed. São Paulo: Pharmabooks, 2015. TAYLOR, L. et al. Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use. Journal of the International Society of Sports Nutrition. DOI: 10.1186/s12970-016-0113-3. 2016. Disponível em:< http://jissn.biomedcentral.com/articles/10.1186/s12970-016-0113-3>. Acesso em: 30/09/2016, às 11:48. ® TEACRINE ESTUDOS CLÍNICOS Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use. Background: Theacrine (1,3,7,9-tetramethyluric acid) is a purine alkaloid found in certain coffee (Coffea) species, fruits (Cupuacu [Theobroma grandiflorum]), and tea (Camellia assamica, var. kucha) that has anti-inflammatory, analgesic, and neuro-locomotor properties. Recent preliminary research has also reported increased feelings of energy, reduced fatigue, and strong effects on improving focus, concentration, and motivation to exercise. The purpose of this study was to examine the safety and non-habituating effects of TeaCrine®, a nature-identical, chemically equivalent bioactive version of theacrine. Methods: Sixty healthy men (mean ± SD age, height, weight: 22.9 ± 4.7 years, 183.5 ± 9.2 cm, 86.5 ± 13.7 kg) and women (22.3 ± 4.5 years, 165.2 ± 12.3 cm, 69.0 ± 17.4 kg) were placed into one of three groups: placebo (PLA, n = 20), 200 mg TeaCrine® (LD, n = 19) or 300 mg Teacrine® (HD, n = 21) and ingested their respective supplement once daily for 8 weeks. Primary outcomes were fasting clinical safety markers (heart rate, blood pressure, lipid profiles, hematologic blood counts, biomarkers of liver/kidney/immune function) and energy, focus, concentration, anxiety, motivation to exercise, and POMS measured prior to daily dosing to ascertain potential tachyphylactic responses and habituation effects. Data were analyzed via two-way (group × time) ANOVAs and statistical significance was accepted at p < 0.05. Results: All values for clinical safety markers fell within normal limits and no group × time interactions were noted. No evidence of habituation was noted as baseline values for energy, focus, concentration, anxiety, motivation to exercise, and POMS remained stable in all groups across the 8-week study protocol. Conclusions: These findings support the clinical safety and non-habituating neuro-energetic effects of TeaCrine® supplementation over 8 weeks of daily use (up to 300 mg/day). Moreover, there was no evidence of a tachyphylactic response that is typical of neuroactive agents such as caffeine and other stimulants. The effects of TeacrineTM, a nature-identical purine alkaloid, on subjective measures of cognitive function, psychometric and hemodynamic indices in healthy humans: a randomized, double-blinded crossover pilot trial. Background: Aside from caffeine, there is a relative dearth of evidence regarding natural ingredients that enhance subjective “energy” levels. We have studied a unique, naturally occurring purine alkaloid, present in Camellia assamica variety kucha tea (amongst other botanical sources) that acts on both adenosinergic and dopaminergic pathways that appears to influence multiple neurochemical pathways. As a first step in a series of experiments, we examined the effects of TeaCrine™, a nature-identical, chemically equivalent bioactive compound known as theacrine (1,3,7,9-tetramethyluric acid), in humans. Methods: Using a randomized, double-blinded, within-subject (crossover) design, 15 healthy subjects (mean ± SD age, height, wgt, BMI: 28.3 ± 6.1 y, 175.7 ± 11.5 cm, 89.8 ± 21.7 kg, 29.1 ± 4.7) volunteered to ingest 200 mg of TeaCrine™ (Compound Solutions, Inc., Carlsbad, CA) (TC) or Placebo (PLA). Anchored VAS questionnaires were used to detect changes in various aspects of physical and mental energy and performance; side effect profiles, hemodynamics and biochemical markers of safety were also collected over a 3-hr post-dosing period. A subset of 6 subjects underwent a separate 7-day, open-label, repeated dose study comparing 100 mg, 200 mg and 400 mg of TC. Consent to publish the results was obtained from all participants. Results: The 200 mg dose of TC caused significant improvements in energy (TC: +8.6% vs. PLA: -5.7%, P=0.049) and reductions in fatigue (TC: -6.7% vs. PLA: +5.8%, P=0.04). A trend for improved concentration was also noted (TC: +2.4% vs. PLA: -1.3%, P=0.07). No changes in systemic hemodynamics or side effect profiles were noted. The N=6 cohort study demonstrated moderate to large effect sizes (0.50 to 0.71) with the 200 mg dose of TC over a 7-day period of assessment for the following subjective measures: energy, fatigue, concentration, anxiety, motivation to exercise and libido. Conclusion: These preliminary data support the benefits of acute TeaCrine™ supplementation on subjective “energy” levels and some indices of mental performance. Future studies are underway to confirm these neurotropic effects and also explore potential benefits of TeaCrine™ on objective measures of cognitive and physical performance, inflammation, pain perception, and functional capacity. Cognitive Performance and Mood Following Ingestion of a Theacrine-Containing Dietary Supplement, Caffeine, or Placebo by Young Men and Women. Theacrine is a purine alkaloid found primarily in the leaves of the Camellia Kucha plant and is now included within dietary supplements. To compare the effects of a theacrine-containing dietary supplement with caffeine and placebo on energy and mood, as well as objective measures of cognitive performance, heart rate, and blood pressure, 10 healthy men (20.8 ± 0.7 years) and 10 healthy women (22.2 ± 1.1 years) ingested the dietary supplement TheaTrim (Purus Labs; containing a branded form of theacrine (Teacrine™) and caffeine (150 mg)), caffeine only (150 mg), or a placebo on three different days, separated by approximately one week. Before, and for up to 4 h following, ingestion of the assigned condition, subjects completed a subjective assessment of energy and mood, as well as tests of cognitive performance (trail making test (TMT), digit symbol substitution test (DSST)), and reaction time. Heart rate and blood pressure were measured. No condition or interaction effects were noted for TMT, DSST, or reaction time, despite a trend for improvement in selected variables with both TheaTrim and caffeine treatment. Condition effects or trends were noted for subjective feelings, with values for attentive, alert, focused, and energetic higher for TheaTrim than for placebo and caffeine, while values for lethargic and groggy were lower for TheaTrim than for placebo and caffeine. Heart rate and blood pressure were largely unaffected by treatment. These data indicate that TheaTrim treatment does not result in a statistically significant improvement in cognitive performance but may favorably impact multiple subjective feelings related to energy and mood. A Two-Part Approach to Examine the Effects of Theacrine (TeaCrine®) Supplementation on Oxygen Consumption, Hemodynamic Responses, and Subjective Measures of Cognitive and Psychometric Parameters. Theacrine (1,3,7,9-tetramethyluric acid) is a naturally occurring purine alkaloid, present in Camellia assamica variety kucha tea. Using a two-part approach in humans, the impact of theacrine (TeaCrine®, TC) was used to examine subjective dose-response, daily changes in cognitive and psychometric parameters, and changes in gas exchange and vital signs. All indicators were chosen to better ascertain the previously reported animal and human outcomes involving theacrine administration. Part 1 was a randomized, open-label, dose-response investigation in nine healthy participants whereby three participants ingested 400 mg TC per day and six participants ingested 200 mg/day. Participants recorded subjective changes in cognitive, psychometric, and exercise attributes using 150-mm anchored visual analog scale (VAS) before, and 1, 4, and 6 hours after ingestion
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9.468,645 B2 Owoc (45) Date of Patent: Oct
    USOO9468645B2 (12) United States Patent (10) Patent No.: US 9.468,645 B2 OWOc (45) Date of Patent: Oct. 18, 2016 (54) HIGHLY SOLUBLE PURINE BOACTIVE (2013.01); A61K 9/0019 (2013.01); A61 K COMPOUNDS AND COMPOSITIONS 9/0095 (2013.01); A61K 9/4858 (2013.01); THEREOF A61 K3I/00 (2013.01); A61K 45/06 (2013.01); A23 V 2002/00 (2013.01) (71) Applicant: JHO Intellectual Property Holdings, (58) Field of Classification Search LLC, Davie, FL (US) CPC ..................... A23V 2002/00; A23V 2200/31; (72) Inventor: Jack Owoc, Weston, FL (US) A23V 2250/062: A23V 2250/21: A23V 2250/5108: A23V 2250/5118: A23V (*) Notice: Subject to any disclaimer, the term of this 2250/54246; A23V 2250/54252: A23V patent is extended or adjusted under 35 2250/704; A23V 2250/712: A61K 31/522; U.S.C. 154(b) by 3 days. A61K 2300/00; A61K 45/06; A61 K9/00 See application file for complete search history. (21) Appl. No.: 14/628,626 (56) References Cited (22) Filed: Feb. 23, 2015 U.S. PATENT DOCUMENTS (65) Prior Publication Data 837,282 A * 12/1906 Owoc ....................... EO1B 9/60 US 2015/O238494 A1 Aug. 27, 2015 238,292 5,973,005 A * 10/1999 D'Amelio, Sr. ... CO7C 277/08 514,565 Related U.S. Application Data 2006/0236421 A1* 10, 2006 Pennell ................ C12N 9/1007 800,278 (60) Provisional application No. 61/944,528, filed on Feb. 2009,0257997 A1* 10, 2009 Owoc .................. A61K9/0014 25, 2014. 424/94.1 (51) Int. C. * cited by examiner A6 IK3I/522 (2006.01) A6 IK 45/06 (2006.01) Primary Examiner – Debbie K Ware A2.3L 2/52 (2006.01) (74) Attorney, Agent, or Firm — David W.
    [Show full text]
  • Identification and Characterization of N 9-Methyltransferase Involved In
    ARTICLE https://doi.org/10.1038/s41467-020-15324-7 OPEN Identification and characterization of N9- methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea Yue-Hong Zhang1,2,3,6, Yi-Fang Li1,2,3,6, Yongjin Wang1,3,6, Li Tan1,3, Zhi-Qin Cao1,2,3, Chao Xie1,2,3, Guo Xie4, Hai-Biao Gong1,2,3, Wan-Yang Sun1,2,3, Shu-Hua Ouyang1,2,3, Wen-Jun Duan1,2,3, Xiaoyun Lu1,3, Ke Ding 1,3, ✉ ✉ ✉ ✉ Hiroshi Kurihara1,2,3, Dan Hu 1,2,3 , Zhi-Min Zhang 1,3 , Ikuro Abe 5 & Rong-Rong He 1,2,3 1234567890():,; Caffeine is a major component of xanthine alkaloids and commonly consumed in many popular beverages. Due to its occasional side effects, reduction of caffeine in a natural way is of great importance and economic significance. Recent studies reveal that caffeine can be converted into non-stimulatory theacrine in the rare tea plant Camellia assamica var. kucha (Kucha), which involves oxidation at the C8 and methylation at the N9 positions of caffeine. However, the underlying molecular mechanism remains unclear. Here, we identify the theacrine synthase CkTcS from Kucha, which possesses novel N9-methyltransferase activity using 1,3,7-trimethyluric acid but not caffeine as a substrate, confirming that C8 oxidation takes place prior to N9-methylation. The crystal structure of the CkTcS complex reveals the key residues that are required for the N9-methylation, providing insights into how caffeine N-methyltransferases in tea plants have evolved to catalyze regioselective N-methylation through fine tuning of their active sites.
    [Show full text]
  • Pharmacokinetics of Caffeine: a Systematic Analysis of Reported Data
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.12.452094; this version posted August 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing Jan Grzegorzewski 1, Florian Bartsch 1, Adrian Koller¨ 1, and Matthias Konig¨ 1;∗ 1Institute for Theoretical Biology, Humboldt-University Berlin, Invalidenstraße 110, 10115 Berlin, Germany Correspondence*: Matthias Konig¨ [email protected] ABSTRACT Caffeine is by far the most ubiquitous psychostimulant worldwide found in tea, coffee, cocoa, energy drinks, and many other beverages and food. Caffeine is almost exclusively metabolized in the liver by the cytochrome P-450 enzyme system to the main product paraxanthine and the additional products theobromine and theophylline. Besides its stimulating properties, two important applications of caffeine are metabolic phenotyping of cytochrome P450 1A2 (CYP1A2) and liver function testing. An open challenge in this context is to identify underlying causes of the large inter-individual variability in caffeine pharmacokinetics. Data is urgently needed to understand and quantify confounding factors such as lifestyle (e.g. smoking), the effects of drug-caffeine interactions (e.g. medication metabolized via CYP1A2), and the effect of disease. Here we report the first integrative and systematic analysis of data on caffeine pharmacokinetics from 148 publications and provide a comprehensive high-quality data set on the pharmacokinetics of caffeine, caffeine metabolites, and their metabolic ratios in human adults. The data set is enriched by meta-data on the characteristics of studied patient cohorts and subjects (e.g.
    [Show full text]
  • Caffeine and Chlorogenic Acid Contents Among Wild Coffea
    Food Chemistry Food Chemistry 93 (2005) 135–139 www.elsevier.com/locate/foodchem Qualitative relationship between caffeine and chlorogenic acid contents among wild Coffea species C. Campa, S. Doulbeau, S. Dussert, S. Hamon, M. Noirot * Centre IRD of Montpellier, B.P. 64501, 34394 Montpellier Cedex 5, France Received 28 June 2004; received in revised form 13 October 2004; accepted 13 October 2004 Abstract Chlorogenic acids, sensu largo (CGA), are secondary metabolites of great economic importance in coffee: their accumulation in green beans contributes to coffee drink bitterness. Previous evaluations have already focussed on wild species of coffee trees, but this assessment included six new taxa from Cameroon and Congo and involved a simplified method that generated more accurate results. Five main results were obtained: (1) Cameroon and Congo were found to be a centre of diversity, encompassing the entire range of CGA content from 0.8% to 11.9% dry matter basis (dmb); (2) three groups of coffee tree species – CGA1, CGA2 and CGA3 – were established on the basis of discontinuities; (3) means were 1.4%, 5.6% and 9.9% dmb, respectively; (4) there was a qualitative relation- ship between caffeine and ACG content distribution; (5) only a small part of the CGA is trapped by caffeine as caffeine chlorogenate. Ó 2004 Elsevier Ltd. All rights reserved. Keywords: Coffeae; Caffeine; Chlorogenic acids 1. Introduction lic acid [feruloylquinic acids (FQA)] and represent 98% of all CGAs (Clifford, 1985; Morishita, Iwahashi, & Two coffee species, C. canephora and C. arabica, are Kido, 1989). There are also some minor compounds, cultivated worldwide. However, these species only repre- such as esters of feruloyl-caffeoylquinic acids (FCQA), sent a small proportion of the worldÕs coffee genetic re- caffeoyl-feruloylquinic acids (CFQA) or p-coumaric acid sources as, in the wild, the Coffea subgenus (Coffea (p-CoQA).
    [Show full text]
  • Theacrine Attenuates Myocardial Fibrosis After Myocardial Infarction Via the SIRT3/Β-Catenin/ Pparγ Pathway in Estrogen-Deficient Mice
    European Review for Medical and Pharmacological Sciences 2019; 23: 5477-5486 Theacrine attenuates myocardial fibrosis after myocardial infarction via the SIRT3/β-catenin/ PPARγ pathway in estrogen-deficient mice L.-L. SONG1, Y. ZHANG2, X.-R. ZHANG3, Y.-N. SONG4, H.-Z. DAI5 1Department of Critical Care Medicine, Weifang Hanting District People’s Hospital, Weifang, China 2Department of Respiratory Medicine, Weifang Hanting District People’s Hospital, Weifang, China 3Department of Pharmacology, Weifang Medical University, Weifang, China 4Department of Breast and Thyroid Surgery, The Traditional Chinese Medicine Hospital of Weifang, Weifang, China 5Department of Emergency, The Affiliated Hospital of Weifang Medical University, Weifang, China Abstract. – OBJECTIVE: To investigate the myocardial apoptosis were clearly aggravated, role of theacrine in the protection of ventricular and the SIRT3 expression was decreased at 28 remodeling and chronic heart failure after myo- days after myocardial infarction. The theacrine cardial infarction in the estrogen-deficient mice. could improve the cardiac function after the MATERIALS AND METHODS: Female myocardial infarction in estrogen-deficient mice C57BL/6 mice aged 8 weeks old were selected and relieve both myocardial fibrosis and myo- and then subjected to bilateral oophorectomy. cardial apoptosis during chronic remodeling af- At 7 days after surgery, the models of the myo- ter myocardial infarction in estrogen-deficient cardial infarction were established by ligating mice. After the intervention with theacrine, the the anterior descending coronary artery. On the estrogen-deficient mice with myocardial infarc- first day after myocardial infarction, Theacrine tion had up-regulated SIRT3 and PPARγ levels (20 mg/kg) was administered via gavage for con- and a reduced β-catenin level in the heart.
    [Show full text]
  • Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times
    Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Traditional Herbal Medicines for Modern Times Each volume in this series provides academia, health sciences, and the herbal medicines industry with in-depth coverage of the herbal remedies for infectious diseases, certain medical conditions, or the plant medicines of a particular country. Series Editor: Dr. Roland Hardman Volume 1 Shengmai San, edited by Kam-Ming Ko Volume 2 Rasayana: Ayurvedic Herbs for Rejuvenation and Longevity, by H.S. Puri Volume 3 Sho-Saiko-To: (Xiao-Chai-Hu-Tang) Scientific Evaluation and Clinical Applications, by Yukio Ogihara and Masaki Aburada Volume 4 Traditional Medicinal Plants and Malaria, edited by Merlin Willcox, Gerard Bodeker, and Philippe Rasoanaivo Volume 5 Juzen-taiho-to (Shi-Quan-Da-Bu-Tang): Scientific Evaluation and Clinical Applications, edited by Haruki Yamada and Ikuo Saiki Volume 6 Traditional Medicines for Modern Times: Antidiabetic Plants, edited by Amala Soumyanath Volume 7 Bupleurum Species: Scientific Evaluation and Clinical Applications, edited by Sheng-Li Pan Traditional Herbal Medicines for Modern Times Herbal Principles in Cosmetics Properties and Mechanisms of Action Bruno Burlando, Luisella Verotta, Laura Cornara, and Elisa Bottini-Massa Cover art design by Carlo Del Vecchio. CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2010 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4398-1214-3 (Ebook-PDF) This book contains information obtained from authentic and highly regarded sources.
    [Show full text]
  • The Two Tortoitumia Ultimate Tatli Himin
    THETWO TORTOITUMIAUS 20180104248A1ULTIMATE TATLI HIMIN ( 19) United States ( 12) Patent Application Publication ( 10 ) Pub . No. : US 2018 /0104248 A1 Lopez et al. (43 ) Pub . Date : Apr . 19 , 2018 ( 54 ) THEACRINE -BASED SUPPLEMENT AND Publication Classification METHOD OF USE THEREOF IN A (51 ) Int. Cl. SYNERGISTIC COMBINATION WITH A61K 31/ 522 ( 2006 . 01 ) CAFFEINE C07D 487/ 04 (2006 . 01) (52 ) U . S . CI. @( 71 ) Applicant : Ortho - Nutra, LLC , Morganville , NJ CPC .. A61K 31/ 522 ( 2013 .01 ) ; C07D 487 /04 (US ) ( 2013. 01 ) @(72 ) Inventors : Hector L Lopez , Cream Ridge , NJ (US ) ; Shawn Wells , Lewisville , TX (US ) ; Tim N . Ziegenfuss , Chardon , OH (57 ) ABSTRACT (US ) A human dietary supplement comprises theacrine and @( 73 ) Assignee : Ortho -Nutra , LLC , Morganville , NJ optionally other compounds that modulate the effects of theacrine . Uses for the theacrine - containing supplement (US ) include improvement of at least one ofmood , energy, focus, concentration or sexual desire or a reduction of at least one (21 ) Appl. No. : 15 /600 , 371 of anxiety or fatigue. A synergistic composition comprises ( 22 ) Filed : May 19 , 2017 co -administration of theacrine and caffeine , wherein the co - administered caffeine reduces theacrine oral clearance Related U . S . Application Data (CL / F ) and oral volume of distribution (Vd / F ) . In addition , the co - administered caffeine increases area under the plasma (63 ) Continuation - in -part of application No. 14 / 539, 726 , concentration time curve ( AUC ) of theacrine , and increases filed on Nov. 12 , 2014 . theacrine maximum plasma concentration ( Cmax ) in com (60 ) Provisional application No .61 / 903 ,362 , filed on Nov . parison with the corresponding pharmacokinetic parameters 12 , 2013 .
    [Show full text]
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction
    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
    [Show full text]
  • The Effects of Teacrine and Caffeine on Endurance and Cognitive
    THE EFFECTS OF TEACRINE AND CAFFEINE ON ENDURANCE AND COGNITIVE PERFORMANCE DURING A SIMULATED MATCH IN HIGH-LEVEL SOCCER PLAYERS By MARISSA L. BELLO A thesis submitted to the School of Graduate Studies Rutgers, The State University of New Jersey In partial fulfillment of the requirements For the degree of Master of Science Graduate Program in Kinesiology and Applied Physiology Written under the direction of Shawn M. Arent And approved by ___________________ ___________________ ___________________ New Brunswick, NJ [January 2019] ABSTRACT OF THE THESIS The Effects of Teacrine and Caffeine on Endurance and Cognitive Performance During a Simulated Match in High-Level Soccer Players by MARISSA L. BELLO Thesis Director Shawn M. Arent Theacrine (1,3,7,9-tetramethyluric-acid) is a pure alkaloid with a similar structure to caffeine and acts comparably as an adenosine receptor antagonist. Early studies have shown non-habituating effects, including increases in energy, focus, and concentration in Teacrine®, the compound containing pure theacrine. PURPOSE: to determine and compare the effects of Teacrine® and caffeine on cognitive performance and time-to-exhaustion during a simulated soccer game in high- level male and female athletes. METHODS: Elite male and female soccer players (N=24; MAge=20.96±2.05y, MMaleVO2max=55.31±3.39mL/O2/kg, MFemaleVO2max=50.97±3.90mL/O2/kg) completed a simulated 90-min soccer match protocol on a treadmill, with cognitive testing including simple reaction time (SRT); choice-RT during a go/no-go task (CRT); and complex-RT during a dual task of go/no go (COGRT) with distraction questions at halftime, and end-of-game.
    [Show full text]
  • LC–MS/MS) Method for Characterizing Caffeine, Methylliberine, and Theacrine Pharmacokinetics in Humans Yan-Hong Wanga, Goutam Mondala, Matthew Butawanb, Richard J
    Journal of Chromatography B 1155 (2020) 122278 Contents lists available at ScienceDirect Journal of Chromatography B journal homepage: www.elsevier.com/locate/jchromb Development of a liquid chromatography-tandem mass spectrometry T (LC–MS/MS) method for characterizing caffeine, methylliberine, and theacrine pharmacokinetics in humans Yan-Hong Wanga, Goutam Mondala, Matthew Butawanb, Richard J. Bloomerb, ⁎ Charles R. Yatesa,c, a The National Center for Natural Products Research, University of Mississippi, Oxford, MS, USA b Cardiorespiratory/Metabolic Laboratory, School of Health Studies, University of Memphis, Memphis, TN, USA c NPI, LLC, Oxford, MS, USA ARTICLE INFO ABSTRACT Keywords: Coffea liberica possesses stimulant properties without accumulating the methylxanthine caffeine. The basis for LC-MS/MS this peculiar observation is that methylurates (e.g., theacrine and methylliberine) have replaced caffeine. The Caffeine stimulant properties of methylurates, alone and in combination with caffeine, have recently been investigated. Methylliberine However, human pharmacokinetics and LC-MS/MS methods for simultaneous measurement of methylxanthines Theacrine and methylurates are lacking. To address this deficiency, we conducted a pharmacokinetic study in which Human pharmacokinetics subjects (n = 12) were orally administered caffeine (150 mg), methylliberine (Dynamine™, 100 mg), and theacrine (TeaCrine®, 50 mg) followed by blood sampling over 24 h. Liquid-liquid extraction of plasma samples containing purine alkaloids and internal standard (13C-Caffeine) were analyzed using a C18 reversed-phase column and gradient elution (acetonitrile and water, both containing 0.1% formic acid). A Waters Xevo TQ-S tandem mass spectrometer (positive mode) was used to detect caffeine, methylliberine, theacrine, and IS tran- sitions of m/z 195.11 → 138.01, 225.12 → 168.02, 225.12 → 167.95, and 198.1 → 140.07, respectively.
    [Show full text]
  • Assessment of Pharmacokinetic Interaction Potential Between Caffeine and Methylliberine
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.05.21249234; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Assessment of Pharmacokinetic Interaction Potential Between Caffeine and Methylliberine Running Title: Pharmacokinetics of Dynamine Authors: Goutam Mondal, PhD1 Yan-Hong Wang, PhD1 Matthew Butawan, BS2 Richard J. Bloomer, PhD2 Charles R. Yates, PharmD, PhD1,3 Affiliations: 1The National Center for Natural Products Research, University of Mississippi, Oxford, MS, USA 2Cardiorespiratory/Metabolic Laboratory, School of Health Studies, University of Memphis, Memphis, TN, USA 3NPI, LLC, Oxford, MS Correspondence should be sent to: Charles R. Yates Thad Cochran Research Center West National Center for Natural Products Research Oxford, MS, 38677-1848 Phone: (662) 915-6994 Email: [email protected] Key Words: caffeine, methylliberine, theacrine, and pharmacokinetics NOTE: This preprint reports new research that has not been certified1 by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.01.05.21249234; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Abstract Methylliberine and theacrine are methylurates found in the leaves of various Coffea species and Camellia assamica var. kucha, respectively. We previously demonstrated that the methylxanthine caffeine increased theacrine’s oral bioavailability in humans.
    [Show full text]
  • The Two Tonditionwinkturtin
    THETWO TONDITIONWINKTURTINUS 20170232103A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0232103 A1 Soane et al. (43 ) Pub. Date : Aug . 17, 2017 ( 54 ) EXCIPIENT COMPOUNDS FOR plication No . 62/ 245 , 513 , filed on Oct . 23, 2015 , BIOPOLYMER FORMULATIONS provisional application No . 62/ 245 ,513 , filed on Oct . (71 ) Applicant : ReForm Biologics , LLC , Cambridge , 23 , 2015 . MA (US ) Publication Classification (51 ) Int. Cl. (72 ) Inventors : David S . Soane , Palm Beach , FL (US ) ; A61K 39 /395 ( 2006 . 01 ) Philip Wuthrich , Belmont, MA (US ) ; A61K 47 / 12 (2006 . 01 ) Rosa Casado Portilla , Peabody , MA CO7K 16 /22 ( 2006 .01 ) (US ) ; Robert P . Mahoney , Newbury , A61K 47 /22 (2006 . 01 ) MA (US ) ; Mark Moody , Concord , MA CO7K 16 / 24 ( 2006 .01 ) (US ) ; Daniel G . Greene , Belmont , MA COZK 16 / 32 ( 2006 .01 ) (US ) (52 ) U . S . CI. CPC . .. A61K 39 / 39591 (2013 . 01 ) ; CO7K 16 / 241 ( 21) Appl . No. : 15 /331 , 197 ( 2013 . 01 ) ; CO7K 16 / 32 (2013 .01 ) ; CO7K 16 / 22 ( 2013 . 01 ) ; A61K 47/ 48215 ( 2013 .01 ) ; A61K (22 ) Filed : Oct . 21 , 2016 47 / 22 ( 2013 . 01 ) ; A61K 47 / 12 ( 2013 . 01) ; COZK 2317 /21 ( 2013 .01 ) ; CO7K 2317 /24 (2013 .01 ) Related U . S . Application Data ( 57 ) ABSTRACT (63 ) Continuation - in -part of application No . 14 / 966 ,549 , The invention encompasses formulations and methods for filed on Dec. 11 , 2015 , now Pat . No . 9 ,605 , 051 , which the production thereof that permit the delivery of concen is a continuation of application No . 14 /744 , 847 , filed trated protein solutions. The inventive methods can yield a on Jun .
    [Show full text]